A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
A Multi-center, 2-Part Study to Evaluate the Pharmacokinetics Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
SP
-
Sao Paulo, SP, Brazil, 04717-004
- MSD
-
-
-
-
-
Mexico City, Mexico, 1090
- MSD
-
-
-
-
-
Madrid, Spain, 28027
- Merck Sharp and Dohme de Espana S.A.
-
-
-
-
-
Istanbul, Turkey
- Merck Sharp & Dohme Ilaclari Ltd. Sti
-
-
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Call for Information (Investigational Site 0003)
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Call for Information (Investigational Site 0022)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is scheduled to have surgery requiring a 48 hour (Part I) or 24 hour (Part II) hospital stay
- Participant is scheduled to receive general anesthesia
- Participant is scheduled to receive opioids (e.g. morphine or fentanyl)
- Female participants of childbearing potential must have negative pregnancy test prior to drug administration
- A female participant who is of reproductive potential must agree to remain abstinent or use a barrier form of contraception for at least 14 days prior to, throughout, and for at least one month following the last dose of study medication
- Participant weighs 6 kg or more
Exclusion Criteria:
- Participant is undergoing surgery for a life-threatening condition
- Participant is pregnant or breast feeding
- Participant has vomited within 24 hours prior to surgery
- Participant has a known history of QT prolongation or is currently taking other medicinal products that lead to QT prolongation
- Participant has an active infection (e.g., pneumonia), congestive heart failure, bradyarrythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction), evidence of any clinically significant respiratory, metabolic, hepatic, renal dysfunction, or a history of any illness, including morbid obesity, that might pose unwarranted risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part 1: Oral Aprepitant
In Study Part 1, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
|
Aprepitant administered orally or intraveously.
Other Names:
|
|
Experimental: Part 2: Oral Aprepitant
In Study Part 2, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
|
Aprepitant administered orally or intraveously.
Other Names:
|
|
Active Comparator: Part 2: Intravenous Ondansetron
In Study Part 2, participants aged 6 months to 17 years received a single intravenous dose of ondansetron on Day 1.
|
Ondansetron administered intravenously.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Curve From 0-48 (AUC0-48) of Aprepitant Following a Single Oral Dose in Study Part 1
Time Frame: Pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post-dose
|
Blood samples of 0.5 mL were collected from participants for the analysis of AUC0-48 at specified time points: pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post aprepitant single dose.
|
Pre-dose, and 1, 2, 3, 4, 8, 12, 24, and 48 hours post-dose
|
|
Maximum Plasma Concentration (Cmax) of Aprepitant Following a Single Oral Dose in Study Part 1
Time Frame: 48 Hours Post-Dose
|
Blood samples were collected from participants for the analysis of Cmax up to 48 hours after dosing.
|
48 Hours Post-Dose
|
|
Time to Maximum Plasma Concentration (Tmax) of Aprepitant Following a Single Oral Dose in Study Part 1
Time Frame: 48 Hours Post-Dose
|
Blood samples were collected from participants for the analysis of Tmax up to 48 hours after dosing.
|
48 Hours Post-Dose
|
|
Plasma Concentration of Aprepitant at 24 Hours (C24 hr) Following a Single Oral Dose in Study Part 1
Time Frame: 24 Hours Post-Dose
|
Blood samples were collected from participants for the analysis of C24 hr at 24 hours after dosing.
N/A indicates that >50% of measurements were below the lower level of quantitaion (LLOQ).
|
24 Hours Post-Dose
|
|
Plasma Concentration of Aprepitant at 48 Hours (C48 hr) Following a Single Oral Dose in Study Part 1
Time Frame: 48 Hours Post-Dose
|
The mean plasma concentration of aprepitant was evaluated in participants at 48 hours following a single oral dose.
|
48 Hours Post-Dose
|
|
Number of Participants Experiencing Adverse Events (AEs)
Time Frame: Up to 21 Days Post-Surgery
|
Up to 21 Days Post-Surgery
|
|
|
Number of Participants Discontinuing Study Treatment Due to AEs
Time Frame: Day 1
|
Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With No Vomiting Up to 24 Hours Following Surgery in Study Part 2
Time Frame: Up to 24 Hours
|
Up to 24 Hours
|
|
|
Number of Participants With Complete Response Up to 24 Hours Following Surgery in Study Part 2
Time Frame: Up to 24 Hours
|
Complete response was defined as no vomiting and no use of rescue medication in 0-24 hours post-surgery.
|
Up to 24 Hours
|
|
Number of Participants With No Vomiting Up to 48 Hours Following Surgery Ini Study Part 2
Time Frame: Up to 48 Hours
|
Up to 48 Hours
|
|
|
Number of Participants With Complete Response Up to 48 Hours Following Surgery in Study Part 2
Time Frame: Up to 48 Hours
|
Complete response was defined as no vomiting and no use of rescue medication in 0-48 hours post-surgery.
|
Up to 48 Hours
|
|
Number of Participants With Vomiting Frequency in Study Part 2
Time Frame: Up to 24 Hours
|
Up to 24 Hours
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Signs and Symptoms, Digestive
- Nausea
- Vomiting
- Postoperative Nausea and Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Dermatologic Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Antagonists
- Anti-Anxiety Agents
- Antipruritics
- Neurokinin-1 Receptor Antagonists
- Ondansetron
- Aprepitant
Other Study ID Numbers
Other Study ID Numbers
- 0869-148
- 2008_569 (Other Identifier: Merck)
- 2008-003178-17 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.